Corient Private Wealth LLC Has $65.55 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Corient Private Wealth LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 278,566 shares of the biopharmaceutical company’s stock after acquiring an additional 81 shares during the period. Corient Private Wealth LLC’s holdings in Alnylam Pharmaceuticals were worth $65,549,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of ALNY. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $61,160,000. Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $41,529,000. Truist Financial Corp boosted its stake in shares of Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after buying an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after buying an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after acquiring an additional 2,285 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALNY. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Scotiabank reduced their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday, February 14th. Sanford C. Bernstein dropped their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ ALNY opened at $241.76 on Monday. The firm has a 50 day moving average price of $255.17 and a two-hundred day moving average price of $259.96. The stock has a market cap of $31.30 billion, a P/E ratio of -111.41 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 over the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.